Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CRDL
CRDL logo

CRDL Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.100
Open
1.030
VWAP
1.07
Vol
679.49K
Mkt Cap
120.61M
Low
1.030
Amount
727.05K
EV/EBITDA(TTM)
--
Total Shares
111.68M
EV
148.31M
EV/OCF(TTM)
--
P/S(TTM)
--
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Show More

Events Timeline

(ET)
2025-08-06
11:45:52
Roth bullish on Cardiol, says trial results enough to attract larger partner
select
2025-08-06
10:08:13
Cardiol ARCHER study not statistically significant, says Canaccord
select
2025-08-06
09:12:05
Cardiol data readout positive and not priced in, says H.C. Wainwright
select
2025-08-06
09:09:13
Cardiol Therapeutics announces Phase II ARCHER results in myocarditis
select

News

seekingalpha
8.5
01-16seekingalpha
Cardiol Therapeutics (CRDL) Raises $13.5M Through Bought-Deal Private Placement at $1.30/Unit
  • Funding Size: Cardiol Therapeutics has entered into a bought-deal agreement with Canaccord Genuity to issue 10.38 million units at $1.30 each, successfully raising $13.5 million, thereby strengthening its financial position for future growth.
  • Over-Allotment Option: The underwriter has the option to purchase an additional 10% of the units, potentially increasing proceeds by $1.35 million, providing the company with further funding flexibility.
  • Unit Composition: Each unit consists of one Class A common share and one-half of a common share purchase warrant, which can be exercised at $1.75 per share for 24 months post-issuance, enhancing potential returns for investors.
  • Use of Proceeds: The proceeds from this financing will be used to advance research and clinical development programs, as well as for working capital and general corporate purposes, reflecting the company's strategic planning for future growth.
Benzinga
2.0
2025-12-02Benzinga
MongoDB Shares Surge Over 22%; Check Out 20 Stocks Making Moves in Premarket Trading
  • MongoDB's Strong Performance: MongoDB Inc. shares surged 22.8% in pre-market trading after reporting third-quarter revenue of $628.31 million, exceeding analyst expectations, and raising its FY26 guidance.

  • Other Notable Gainers: Taoping Inc. saw a 64.5% increase after announcing an acquisition, while Fitell Corp. rose 37.6% following a repurchase program announcement.

  • Significant Losers: Janux Therapeutics Inc. experienced a 39.3% drop in pre-market trading after releasing updated interim data, while American Bitcoin Corp. fell 17% after a previous decline.

  • Market Overview: The article highlights various stocks moving in pre-market trading, showcasing both significant gainers and losers, reflecting market volatility.

Benzinga
4.0
2025-12-01Benzinga
HC Wainwright & Co. Affirms Buy Rating for Cardiol Therapeutics, Keeps $9 Price Target Intact
  • Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders succeed in the markets.

  • Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from timely alerts and insights.

  • Trade Alerts: Users can receive the fastest news alerts to ensure they never miss a trading opportunity.

NASDAQ.COM
9.0
2025-07-22NASDAQ.COM
Cardiol To Report ARCHER Study Data Within The Next Two Weeks
  • Clinical Milestone for Cardiol Therapeutics: Cardiol Therapeutics Inc. is nearing a significant milestone with its lead asset, CardiolRx, an oral solution in clinical development for heart disease, specifically in a phase II study for acute myocarditis called ARCHER, which has enrolled over 100 patients across multiple countries.

  • Database Lock and Upcoming Results: The company has completed the database lock for the ARCHER study, a crucial step before statistical analysis, with topline results expected within two weeks.

Benzinga
4.0
2025-06-02Benzinga
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
  • Analyst Ratings Updates: Several Wall Street analysts have initiated coverage on various companies, including Aspen Insurance with a Neutral rating and a price target of $38, Cardiol Therapeutics with a Buy rating and a target of $9, Shake Shack with a Sector Weight rating, Visa with a Buy rating and a target of $400, and RPM International with a Buy rating and a target of $135.

  • Current Stock Prices: As of Friday, Aspen Insurance shares closed at $34.30, Cardiol Therapeutics at $1.4251, Shake Shack at $129.79, Visa at $365.19, and RPM International at $113.84.

Benzinga
4.0
2025-06-02Benzinga
HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9
  • Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.

Wall Street analysts forecast CRDL stock price to rise
2 Analyst Rating
Wall Street analysts forecast CRDL stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
8.00
Averages
8.50
High
9.00
Current: 0.000
sliders
Low
8.00
Averages
8.50
High
9.00
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$9
AI Analysis
2025-06-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
AI Analysis
2025-06-02
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Cardiol Therapeutics with a Buy rating and $9 price target. Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-04-16
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2025-04-16
Reiterates
Strong Buy
Reason

Valuation Metrics

The current forward P/E ratio for Cardiol Therapeutics Inc (CRDL.O) is -3.29, compared to its 5-year average forward P/E of -4.03. For a more detailed relative valuation and DCF analysis to assess Cardiol Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.03
Current PE
-3.29
Overvalued PE
-2.14
Undervalued PE
-5.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.61
Current EV/EBITDA
-4.43
Overvalued EV/EBITDA
-0.75
Undervalued EV/EBITDA
-6.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.05
Current PS
0.00
Overvalued PS
60.64
Undervalued PS
-32.55

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top pick to buy today <$3
Intellectia · 34 candidates
Market Cap: >= 100.00MPrice: $0.50 - $3.00Moving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 60
Ticker
Name
Market Cap$
top bottom
ABOS logo
ABOS
Acumen Pharmaceuticals Inc
147.19M
CIG logo
CIG
Energy of Minas Gerais Co
6.16B
CRDL logo
CRDL
Cardiol Therapeutics Inc
112.24M
ROMA logo
ROMA
Roma Green Finance Ltd
119.13M
GORO logo
GORO
Gold Resource Corp
242.79M
ALTO logo
ALTO
Alto Ingredients Inc
199.16M

Whales Holding CRDL

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cardiol Therapeutics Inc (CRDL) stock price today?

The current price of CRDL is 1.08 USD — it has increased 1.89

What is Cardiol Therapeutics Inc (CRDL)'s business?

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

What is the price predicton of CRDL Stock?

Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cardiol Therapeutics Inc (CRDL)'s revenue for the last quarter?

Cardiol Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Cardiol Therapeutics Inc (CRDL)'s earnings per share (EPS) for the last quarter?

Cardiol Therapeutics Inc. EPS for the last quarter amounts to -0.12 USD, decreased -33.33

How many employees does Cardiol Therapeutics Inc (CRDL). have?

Cardiol Therapeutics Inc (CRDL) has 18 emplpoyees as of March 12 2026.

What is Cardiol Therapeutics Inc (CRDL) market cap?

Today CRDL has the market capitalization of 120.61M USD.